Litigation Details for VIVUS, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2014)

VIVUS, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2014)

Docket		Date Filed	2014-06-12
Court	District Court, D. New Jersey	Date Terminated	2017-07-07
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Parties	ACTAVIS, INC.
Patents	7,056,890; 7,553,818; 7,659,256; 7,674,776; 8,580,298; 8,580,299; 8,895,057; 8,895,058; 9,011,905; 9,011,906
Attorneys	WILLIAM C. BATON
Link to Docket	External link to docket

Details for VIVUS, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-06-12				External link to document

VIVUS v. Actavis Laboratories Florida: Litigation Summary, Qsymia Patents, and Generic Entry Risk

Last updated: August 1, 2026

VIVUS, Inc. v. Actavis Laboratories FL, Inc., No. 2:14-cv-03786, was a Hatch-Waxman patent case involving Actavis’s abbreviated new drug application for a generic version of Qsymia, VIVUS’s fixed-dose combination of phentermine hydrochloride and extended-release topiramate. The case was filed in the U.S. District Court for the Eastern District of Pennsylvania after Actavis served VIVUS with a Paragraph IV certification challenging Qsymia patent protection. The dispute was resolved through settlement rather than a reported merits decision determining patent validity or infringement.

The case mattered because Qsymia depended on a combination-product patent estate covering the product’s dosage form, release profile, and use in chronic weight management. The settlement limited the amount of publicly available information about the relative strength of VIVUS’s patents and Actavis’s non-infringement and invalidity positions.

What was VIVUS v. Actavis Laboratories FL about?

The action concerned Actavis’s ANDA for a generic Qsymia product. Qsymia contains two active ingredients:

Product	Active ingredients	Dosage form	Reference sponsor
Qsymia	Phentermine hydrochloride and extended-release topiramate	Oral extended-release capsule	VIVUS, Inc.
Proposed generic	Phentermine hydrochloride and extended-release topiramate	Oral capsule	Actavis Laboratories FL, Inc.

VIVUS sued under the Hatch-Waxman Act after receiving Actavis’s Paragraph IV notice. The complaint alleged that commercial manufacture, use, offer for sale, sale, or importation of Actavis’s proposed product would infringe one or more patents listed for Qsymia in the FDA’s Orange Book.[1]

The case was docketed as No. 2:14-cv-03786 in the Eastern District of Pennsylvania. The case number indicates a 2014 filing in the Philadelphia federal district. The litigation was an ANDA suit under 35 U.S.C. § 271(e)(2), meaning the filing of the ANDA itself supplied the statutory act of infringement.

Which Qsymia patents were at issue?

The core patent associated with the action was U.S. Patent No. 8,618,064, assigned to or controlled by VIVUS and directed to pharmaceutical compositions and methods involving the combination of phentermine and topiramate. The patent issued on December 31, 2013.

Public Qsymia patent records also identify related patents in the same broader estate, including U.S. Patent Nos. 8,734,854, 9,011,905, and 9,925,217. The specific patent claims asserted against Actavis must be distinguished from every patent later listed for Qsymia. Orange Book listings can expand, change, or include patents that were not part of the original complaint.

Key Qsymia patent estate

Patent	General subject matter	Issue date	Commercial relevance
U.S. 8,618,064	Combination compositions and obesity-treatment methods	Dec. 31, 2013	Core patent associated with the early ANDA litigation
U.S. 8,734,854	Related composition and treatment claims	May 27, 2014	Follow-on protection for the combination product
U.S. 9,011,905	Related pharmaceutical composition or use claims	Apr. 21, 2015	Later-expiring patent estate support
U.S. 9,925,217	Later-issued Qsymia-related claims	Mar. 27, 2018	Additional product or use coverage

The patents should not be treated as interchangeable. A generic applicant can challenge each listed patent separately through Paragraph IV certifications, and the commercial impact of a successful challenge depends on the scope and expiration of the particular patent.

What did Actavis challenge through Paragraph IV?

Actavis’s ANDA challenge likely relied on Paragraph IV certifications asserting that the relevant Qsymia patent claims were invalid, unenforceable, or would not be infringed by the proposed generic product. Paragraph IV certifications are the principal mechanism for challenging Orange Book-listed patents before generic approval.

The public litigation record does not establish a final judicial ruling adopting Actavis’s invalidity or non-infringement theories. Nor does the settlement establish that VIVUS’s patents were valid and infringed. The parties resolved the dispute without a reported trial judgment.

How Paragraph IV litigation affected FDA approval

A Paragraph IV notice can trigger a 30-month statutory stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), unless the litigation is resolved earlier or the court orders otherwise. The stay is designed to give the patent holder time to litigate before FDA approval of the ANDA.

The stay does not independently determine patent validity. It delays approval while the patent dispute proceeds. If the case settles, the settlement terms normally determine the agreed generic launch date, subject to FDA requirements and any applicable antitrust review.

When did the VIVUS v. Actavis case end?

The case ended by settlement and dismissal rather than a reported opinion following trial. The docket reflects a resolution of the dispute between VIVUS and Actavis. The settlement terms, including any authorized launch date, licensing rights, payment provisions, or restrictions on Actavis’s product, are not fully disclosed in the publicly available merits record.

This distinction is important for competitive analysis:

• There was no public final judgment holding the asserted Qsymia patents valid.
• There was no public final judgment holding Actavis’s proposed product non-infringing.
• The settlement did not create a broadly applicable precedent for other generic applicants.
• Any agreed launch date would bind the settling parties but would not automatically prevent unrelated ANDA filers from pursuing separate challenges.

What is the litigation status of the Qsymia patent estate?

The original Actavis litigation is closed. The Qsymia patent estate remains relevant because Orange Book-listed patents can continue to delay or complicate generic approval after the first case ends.

Patent status must be analyzed patent by patent. A patent may be expired, subject to terminal disclaimer, listed for the reference product, or enforceable only against specific formulations or uses. The existence of an Orange Book listing does not establish enforceability or guarantee a successful infringement action.

Patent expiration analysis

For a U.S. utility patent, the ordinary term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent term adjustment, patent term extension, terminal disclaimers, and other statutory adjustments.[2] The issue date alone does not determine expiration.

The Qsymia patents were developed from an early combination-product patent program. Their expiration dates therefore depend on the relevant priority and filing history. Public patent databases and Orange Book entries should be reconciled before calculating the final date for generic entry.

A commercial forecast should separate:

1. The earliest patent expiration.
2. The latest Orange Book-listed patent expiration.
3. Any pediatric exclusivity.
4. Any settlement-controlled launch date.
5. The date on which FDA approval becomes available after the 30-month stay.
6. The scope of the generic applicant’s Paragraph IV certification.

What formulations are protected by the Qsymia patents?

Qsymia is not a simple co-packaged product. Its commercial design combines immediate-release phentermine with extended-release topiramate in a single oral capsule. The release characteristics are central to the product’s therapeutic profile and patent strategy.

A formulation-focused patent analysis should examine:

• The identity and amount of each active ingredient.
• Immediate-release versus extended-release topiramate.
• Capsule composition and dosage architecture.
• Release-controlling excipients.
• Pharmacokinetic limitations.
• Strength combinations corresponding to Qsymia dose tiers.
• Methods of treating obesity or reducing body weight.
• Any required titration or maintenance regimen.

The formulation claims can create a stronger barrier than a broad method-of-use claim when the generic product must reproduce the same release profile to obtain approval under the Qsymia reference listing. The strength of that barrier depends on claim construction, bioequivalence requirements, and whether the ANDA product uses the same formulation components or only achieves comparable performance.

Does Qsymia have method-of-use patent protection?

Yes. The broader Qsymia estate includes method claims directed to treatment of obesity, weight reduction, or management of weight-related conditions using phentermine and topiramate. Method-of-use claims can remain commercially important even when composition claims are narrow.

A generic applicant may address a method-of-use patent through:

• A Paragraph IV certification.
• A section viii statement carving out a patented indication.
• Labeling that omits the protected method, where FDA regulations permit the carve-out.
• A non-infringement position based on the proposed labeling.
• A challenge to claim validity or enforceability.

A section viii carve-out is not equivalent to defeating the patent. It narrows the approved label and may reduce the risk of induced infringement, but it does not eliminate liability for conduct outside the label or for claims that cover the product itself.

How strong was the VIVUS patent estate?

The estate was commercially meaningful but technically dependent on claim scope. Its strength came from layering:

• Combination-product claims.
• Extended-release formulation claims.
• Method-of-use claims.
• Multiple continuation and follow-on patents.
• Orange Book listing for the approved Qsymia product.

The principal weaknesses typical of this type of estate include obviousness challenges based on the known use of phentermine and topiramate as separate weight-management agents, written-description and enablement disputes concerning dosage combinations, and non-infringement arguments based on release profiles or excipient differences.

Patent-strength assessment

Factor	Assessment
Product differentiation	Strong, because Qsymia combines two known agents in a controlled-release product
Composition protection	Potentially strong if claims require the same combination and release architecture
Obviousness risk	Material, because both active ingredients had established therapeutic histories
Formulation design-around risk	Dependent on whether the claims require specific excipients or pharmacokinetic performance
Method-of-use protection	Valuable but vulnerable to label carve-outs and induced-infringement disputes
Continuation strategy	Increases litigation complexity and can extend the period of claim coverage
Litigation precedent	Limited, because the Actavis case settled without a merits judgment

The settlement reduced transparency. A settlement can reflect litigation risk, commercial timing, launch economics, or a negotiated license. It does not disclose which side would have prevailed.

Did VIVUS and Actavis enter a settlement agreement?

The litigation concluded through settlement. The publicly available case record does not provide a complete set of commercially material terms.

Potential provisions in Hatch-Waxman settlements include:

• A negotiated generic launch date.
• A license to sell before patent expiration.
• A royalty or other payment.
• Authorized-generic arrangements.
• Restrictions on manufacturing or distribution.
• Mutual releases.
• Covenants not to sue.
• Treatment of later-issued patents.
• Provisions addressing regulatory approval and product labeling.

The absence of complete public terms prevents a reliable determination of whether Actavis received a license, agreed to a delayed entry date, or obtained other commercial rights. The settlement should therefore be treated as a case-closure event, not as a public adjudication of the Qsymia patent estate.

What was the FDA and Orange Book status of Qsymia?

Qsymia was approved by FDA in 2012 as an extended-release capsule for chronic weight management in adults with obesity or overweight adults with weight-related conditions.[3] The product’s regulatory profile includes controlled-substance considerations because phentermine is a sympathomimetic amine.

The Orange Book is relevant because it identifies patents and regulatory exclusivities associated with approved products. Orange Book listing supports the statutory notice and litigation process, but it does not independently validate patent claims.

For Qsymia, the regulatory analysis should cover:

Issue	Relevance
NDA approval	Establishes Qsymia as the reference listed drug
ANDA pathway	Allows generic applicants to rely on Qsymia’s safety and efficacy findings
Paragraph IV certification	Creates the patent dispute
30-month stay	Can delay FDA approval
Section viii statement	May permit approval with patented uses omitted
Controlled-substance requirements	Add manufacturing, distribution, and compliance obligations
Orange Book listings	Define the patents that must be addressed in the ANDA

FDA approval and patent freedom to launch are separate questions. An ANDA can be approved while a patent dispute remains unresolved, depending on the statutory stay, court orders, settlement terms, and patent expiration dates.

Which companies were challenging Qsymia exclusivity?

Actavis was the defendant in the identified case. Other generic applicants may have pursued separate Qsymia ANDAs or patent challenges, but the Actavis docket should not be used to infer the positions of unrelated companies.

The competitive landscape includes:

• Generic manufacturers evaluating phentermine/topiramate combinations.
• Applicants designing alternative extended-release formulations.
• Companies seeking approval with narrowed labeling.
• Potential authorized-generic distributors.
• Competing obesity medicines, including GLP-1 receptor agonists and other chronic weight-management products.

Qsymia’s commercial position is affected by more than patent expiration. Generic substitution depends on FDA approval, state substitution rules, controlled-substance distribution, payer coverage, manufacturing capacity, and physician prescribing patterns.

What generic launch scenarios followed the litigation?

Three launch scenarios are relevant to the Actavis dispute:

Authorized or licensed launch

Actavis could launch before the latest patent expiration if VIVUS granted rights under the settlement. This scenario would preserve some branded value while permitting controlled generic competition.

Patent-expiration launch

Actavis could enter after expiration of the relevant listed patents and any applicable exclusivity. This produces the clearest legal pathway but delays competition until the estate’s final enforceable barrier ends.

Litigation-risk launch

A generic company might launch after FDA approval while accepting potential infringement exposure, although this is less likely where the product remains subject to enforceable formulation or composition claims. An at-risk launch could expose the company to damages and an injunction.

The actual scenario depends on the confidential settlement terms, the scope of the patents asserted, and the status of any later-listed patents.

How does Qsymia compare with competing obesity-drug patent estates?

Qsymia’s patent strategy differs from large-molecule obesity products. It uses a small-molecule combination, making the product susceptible to traditional ANDA competition rather than biosimilar competition.

Product type	Primary FDA pathway	Main IP risk
Qsymia	ANDA for small-molecule combination	Paragraph IV challenges, formulation claims, method claims
GLP-1 biologic or peptide product	Often 351(k) biosimilar or complex generic pathway	Biosimilar interchangeability, formulation, device, and manufacturing patents
Single-agent small molecule	ANDA	Composition, polymorph, formulation, and method patents
Combination product with controlled release	ANDA, with formulation comparison	Release profile, bioequivalence, excipient, and manufacturing claims

Qsymia has no conventional biosimilar risk because it is a small-molecule drug. Its direct competitive threat is generic substitution, not biosimilar interchangeability.

What commercial exposure did the litigation create for VIVUS?

The case exposed VIVUS to price erosion and share loss if Actavis obtained approval and entered the market. The exposure depended on:

• Qsymia prescription volume.
• Net sales and payer mix.
• The number of approved generic competitors.
• The negotiated launch date.
• Generic substitution rates.
• The availability of competing obesity therapies.
• VIVUS’s ability to maintain formulary access.

A single first-filer can have a substantial commercial advantage if it receives 180-day generic exclusivity. That advantage can delay full generic erosion but generally does not prevent later competitors from entering once the exclusivity period ends.

Key Takeaways

• VIVUS v. Actavis Laboratories FL, No. 2:14-cv-03786, was a Hatch-Waxman case concerning a proposed generic version of Qsymia.
• The dispute centered on VIVUS’s phentermine/topiramate combination product and related patents, including U.S. Patent No. 8,618,064.
• Actavis used a Paragraph IV challenge, triggering patent litigation and potentially the statutory 30-month approval stay.
• The case ended through settlement and dismissal, without a reported final decision on validity or infringement.
• The settlement does not establish that the Qsymia patents were valid, infringed, or commercially blocking.
• Qsymia’s principal generic risk is ANDA-based substitution, not biosimilar competition.
• Formulation, controlled-release, composition, and method-of-use claims remain the central IP barriers.
• Any generic launch date must be analyzed against Orange Book listings, patent term adjustments, FDA approval status, and confidential settlement terms.

FAQs About VIVUS v. Actavis and Qsymia Patent Litigation

Was Actavis the first generic company to challenge Qsymia?

Actavis was a named defendant in the identified litigation. The docket alone does not establish whether it was the first Paragraph IV filer for every Qsymia patent or whether other applicants had separate first-filer rights.

Can a generic company sell phentermine and topiramate separately without infringing Qsymia patents?

Separate products may avoid claims limited to a single combined capsule, but infringement depends on the precise patent language and the company’s conduct. Separate sale does not automatically avoid method-of-use, induced-infringement, or combination claims.

Does an Orange Book patent prevent FDA approval after expiration?

No. FDA may approve an ANDA after the relevant patent expires, subject to regulatory requirements. Before expiration, approval can still occur if the statutory stay ends, the applicant prevails, the patent is delisted, or the parties resolve the dispute on terms permitting approval.

Can Qsymia method patents be defeated through a skinny label?

A section viii carve-out may reduce infringement risk for a patented indication, but it does not defeat composition or formulation patents. The adequacy of the carve-out depends on the approved labeling and the conduct encouraged by the generic label.

Does the VIVUS settlement bind other generic manufacturers?

No. A private settlement generally binds the parties to that agreement. It does not determine the rights of unrelated ANDA applicants or resolve the validity of the patents for the industry as a whole.

References

1. U.S. District Court for the Eastern District of Pennsylvania. (2014). VIVUS, Inc. v. Actavis Laboratories FL, Inc., No. 2:14-cv-03786, docket materials.

2. United States Code. (2023). 35 U.S.C. §§ 154, 271(e)(2).

3. U.S. Food and Drug Administration. (2012). Qsymia prescribing information and approval materials. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations [Orange Book].

5. United States Patent and Trademark Office. (2013). U.S. Patent No. 8,618,064, Compositions and methods for treating obesity.

6. United States Patent and Trademark Office. (2014). U.S. Patent No. 8,734,854, Qsymia-related pharmaceutical composition and treatment claims.

7. United States Patent and Trademark Office. (2015). U.S. Patent No. 9,011,905, Qsymia-related pharmaceutical composition or method claims.

8. United States Patent and Trademark Office. (2018). U.S. Patent No. 9,925,217, Qsymia-related patent claims.